Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate ‘Bersiporocin’ at ERS 2026

104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027 First-in-class PRS inhibitor being developed as a potential new therapeutic option for IPF BARCELONA, Spain and SEOUL, South Korea, Sept. 24, 2026 /PRNewswire/ — Daewoong [...] The post Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Can